Skip to main content

Talis Biomedical Corporation (TLIS)

NASDAQ: TLIS · Delayed Price · USD
5.38
+0.06 (1.13%)
After-hours:Oct 22, 2021 5:22 PM EDT
5.32
-0.41 (-7.16%)
At close: Oct 22, 4:00 PM
Market Cap138.99M
Revenue (ttm)16.84M
Net Income (ttm)n/a
Shares Out25.65M
EPS (ttm)-18.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume162,943
Open5.73
Previous Close5.73
Day's Range5.28 - 5.73
52-Week Range5.28 - 33.90
Betan/a
AnalystsBuy
Price Target7.00 (+31.6%)
Est. Earnings DateNov 9, 2021

About TLIS

Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corpor...

IndustryMedical Devices
IPO DateFeb 12, 2021
Employees133
Stock ExchangeNASDAQ
Ticker SymbolTLIS
Full Company Profile

Financial Performance

In 2020, TLIS's revenue was $10.94 million, an increase of 175.03% compared to the previous year's $3.98 million. Losses were -$91.13 million, 231.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for TLIS stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 31.58% from the latest price.

Price Target
$7.00
(31.58% upside)
Analyst Consensus: Buy

News

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Talis Biomedical Corporatio...

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Talis Biomedical Corporation (“Tal...

1 month ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Talis Biomedical Corporation (TLIS) on Beha...

BENSALEM, Pa.--(BUSINESS WIRE)---- $TLIS #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) inve...

1 month ago - Business Wire

TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis on Behalf of Talis Stockholders and Encourages Invest...

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (“Talis” or the “Compa...

1 month ago - Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Talis Biomedical Corpora...

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...

1 month ago - Business Wire

The Law Offices of Frank R. Cruz Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #investors--The Law Offices of Frank R. Cruz Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

1 month ago - Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $TLIS #investors--The Law Offices of Frank R. Cruz Announces Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

1 month ago - Business Wire

Talis Biomedical Announces CEO Transition

Kim Popovits to serve as interim CEO Kim Popovits to serve as interim CEO

1 month ago - GlobeNewsWire

Talis Biomedical Announces Second Quarter 2021 Financial Results and Business Progress

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

2 months ago - GlobeNewsWire

Talis Biomedical Announces First Quarter 2021 Financial Results and Business Progress

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

5 months ago - GlobeNewsWire

4 Stocks With High Insider Cluster Buys During February and March

According to Insider Cluster Buys, a Premium feature of GuruFocus, four stocks with a high number of unique insider buys during February and March are Camden National Corp. (NASDAQ:CAC), Talis Biomedica...

Other symbols:CACMLVFSGFY
7 months ago - GuruFocus

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

8 months ago - Benzinga

Talis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional S...

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular...

8 months ago - GlobeNewswire

Talis Announces Pricing of Initial Public Offering Nasdaq:TLIS

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular...

8 months ago - GlobeNewswire

Diagnostic testing developer Talis Biomedical files for a $150 million IPO

Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.

8 months ago - NASDAQ

Talis Biomedical IPO Registration Document (S-1)

Talis Biomedical Corporation has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC